Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in Chinese severe eosinophilic asthma
NCT03562195Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2018
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in severe eosinophilic asthma (SEA) comparing Mepolizumab with Placebo (2 arms). Primary endpoint: Rate of Clinically Significant Exacerbations of Asthma at 52 weeks. Started Aug 2018; status: completed.
02
Drugs
mepolizumab
03
Conditions
severe eosinophilic asthma (SEA)
Beyond the preview
Go deeper on NCT03562195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03562195.